Connecticut joins New York, Minnesota, and many other states by considering SB 270, a bill that seeks to limit physician-pharmaceutical industry interaction. During a debate in late February in a Public Health Committee hearing for the Connecticut General Assembly, the bill’s sponsor, Connecticut Attorney General Richard Blumenthal, said that although “certain pharmaceutical drug companies are taking steps toward self-reform,” there’s still a need for “a state law readily enforceable by ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.